• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global Radiopharmaceuticals Market Insight - Product Image

Global Radiopharmaceuticals Market Insight

  • ID: 2754873
  • February 2014
  • Region: Global
  • 450 Pages
  • Kuick Research

FEATURED COMPANIES

  • Actinium Pharmaceuticals
  • Avid Radiopharmaceuticals
  • GE Healthcare
  • Ion Beam Applications
  • Lantheus Medical Imaging
  • Navidea
  • MORE

Radioisotopes are radioactive isotopes having an unstable balance of atomic nucleus. Radioisotopes are produced either by using nuclear research reactor or by using cyclotron. These isotopes emit energy in the form of alpha, beta or gamma when changed to a stable nature. The gamma rays, thus emitted are used in Nuclear medicine, specifically in medical diagnostics.

In this field, the radiation is used to provide diagnostic information about a human body's functioning. Radiotherapy is also used to treat some life-threatening diseases like cancer. Also, it has been observed that the increasing use of radioisotopes is one of the major reasons for a fall in deaths caused by cancer across the globe. It is because of this feature that the demand for radioisotopes or otherwise called radiopharmaceuticals is increasing significantly.

A major part of the radiopharmaceuticals market is dominated by diagnostic radiopharmaceuticals, where, SPECT and PET isotopes are most common. The new innovations in nuclear medicine to target coronary heart disease, Alzheimer's disease, breast cancer, and bone metastasis would be the major drivers of the diagnostic radiopharmaceuticals market READ MORE >

FEATURED COMPANIES

  • Actinium Pharmaceuticals
  • Avid Radiopharmaceuticals
  • GE Healthcare
  • Ion Beam Applications
  • Lantheus Medical Imaging
  • Navidea
  • MORE

1. Global Radiopharmaceuticals Market Outlook
1.1 Market Overview
1.2 Diagnostic & Therapeutic Radiopharmaceuticals
1.3 Market Dynamics
1.4 Radioisotopes Used in Radiopharmaceuticals
1.5 Radiopharmaceuticals in Clinical Development Phase

2. Europe Guidelines for Radiopharmaceuticals
2.1 Physico-Chemical, Biological or Microbiological Tests of Medicinal Products
2.2 Toxicological & Pharmacological Tests
2.3 Clinical Documentation
2.4 Radiation Dosimetry
2.5 Labelling & Packaging

3. US Guidelines for Radiopharmaceuticals
3.1 Clinical Indication
3.2 General Considerations for Safety Assessments
3.3 Clinical Evaluation of Medical Imaging Agents

4. Canada Guidelines for Radiopharmaceuticals
4.1 Use of Positron Emitting Radiopharmaceuticals (PERs) in Basic Research
4.2 Use of Positron Emitting Radiopharmaceuticals in Basic Research involving Humans
4.3 Stability Testing of Existing Drug Substances and Products
4.4 Good Manufacturing Practices (GMP) for Positron Emitting Radiopharmaceuticals (PERs)

5. Radiopharmaceuticals Clinical Trial Insight by Indication, Country & Phase
5.1 Phase Unknown
5.2 Research
5.3 Preclinical
5.4 Clinical
5.5 Phase 0
5.6 Phase I
5.7 Phase I/II
5.8 Phase II
5.9 Phase III
5.10 Preregistration
5.11 Registered

6. Marketed Radiopharmaceuticals by Indication & Country

7. Discontinued & Suspended Radiopharmaceuticals Drug Profiles by Indication, Country & Phase
7.1 Discontinued Clinical Trials for Radiopharmaceuticals
7.2 Suspended Clinical Trials for Radiopharmaceuticals
7.3 No Development Reported

8. Competitive Landscape
8.1 Avid Radiopharmaceuticals
8.2 Actinium Pharmaceuticals
8.3 AREVA Med
8.4 Bayer HealthCare Pharmaceuticals
8.5 Cardinal Health
8.6 Immunomedics
8.7 Lantheus Medical Imaging
8.8 Merck & Co
8.9 Navidea
8.10 Nordion
8.11 Lantheus Medical Imaging
8.12 GE Healthcare
8.13 Ion Beam Applications
8.14 PETNET Solutions (Siemens Healthcare Global)

Tables and Figures:

Table 1-1: Calcium-47 Investigation Properties as Radiopharmaceuticals Drug
Table 1-2: Carbon-11 Investigation Properties as Radiopharmaceuticals Drug
Table 1-3: Carbon-14 Investigation Properties as Radiopharmaceuticals Drug
Table 1-4: Chromium-51 Investigation Properties as Radiopharmaceuticals Drug
Table 1-5: Cobalt-57 Investigation Properties as Radiopharmaceuticals Drug
Table 1-6: Cobalt-58 Investigation Properties as Radiopharmaceuticals Drug
Table 1-7: Erbium-169 Investigation Properties as Radiopharmaceuticals Drug
Table 1-8: Fluorine-18 Investigation Properties as Radiopharmaceuticals Drug
Table 1-9: Gallium-67 Investigation Properties as Radiopharmaceuticals Drug
Table 1-10: Gallium-68 Investigation Properties as Radiopharmaceuticals Drug
Table 1-11: Hydrogen-3 Investigation Properties as Radiopharmaceuticals Drug
Table 1-12: Indium-111 Investigation Properties as Radiopharmaceuticals Drug
Table 1-13: Iodine-123 Investigation Properties as Radiopharmaceuticals Drug
Table 1-14: Iodine-125 Investigation Properties as Radiopharmaceuticals Drug
Table 1-15: Iodine-131 Diagnostic Investigation Properties as Radiopharmaceuticals Drug
Table 1-15: Iodine-131 Therapeutic Investigation Properties as Radiopharmaceuticals Drug
Table 1-16: Iron-59 Investigation Properties as Radiopharmaceuticals Drug
Table 1-17: Krypton-81m Investigation Properties as Radiopharmaceuticals Drug
Table 1-18: Nitrogen-13 Investigation Properties as Radiopharmaceuticals Drug
Table 1-19: Oxygen-15 Investigation Properties as Radiopharmaceuticals Drug
Table 1-20: Phosphorus-32 Investigation Properties as Radiopharmaceuticals Drug
Table 1-21: Radium-223 Investigation Properties as Radiopharmaceuticals Drug
Table 1-22: Rubidium-82 Investigation Properties as Radiopharmaceuticals Drug
Table 1-23: Samarium-153 Investigation Properties as Radiopharmaceuticals Drug
Table 1-24: Selenium-75 Investigation Properties as Radiopharmaceuticals Drug
Table 1-25: Sodium-22 Investigation Properties as Radiopharmaceuticals Drug
Table 1-26: Sodium-24 Investigation Properties as Radiopharmaceuticals Drug
Table 1-27: Strontium-89 Investigation Properties as Radiopharmaceuticals Drug
Table 1-28: Technetium-99m Investigation Properties as Radiopharmaceuticals Drug
Table 1-29: Thallium-201 Investigation Properties as Radiopharmaceuticals Drug
Table 1-30: Xenon-133 Investigation Properties as Radiopharmaceuticals Drug
Table 1-31: Yttrium-90 Investigation Properties as Radiopharmaceuticals Drug

Figure 1-1: Global Radiopharmaceuticals Market (US$ Billion), 2013-2018
Figure 1-2: Global Radiopharmaceuticals Market by Region (%), 2013 & 2018
Figure 1-3: Global Radiopharmaceuticals Market by Region (US$ Billion), 2013 - 2018
Figure 1-4: Target Patient Base for Radiopharmaceuticals (Million), 2013-2018
Figure 1-5: Target Patient Base for Radiopharmaceuticals by Region (%), 2013 & 2018
Figure 1-6: Target Patient Base for Radiopharmaceuticals by Region (Million), 2013 - 2018
Figure 1-7: Radiopharmaceuticals Development by Clinical Phase (%), 2014
Figure 1-8: Radiopharmaceuticals Development by Clinical Phase (Number of Drugs), 2014
Figure 1-9: Suspended & Discontinued Radiopharmaceuticals in Clinical Phase (Number of Drugs), 2014
Figure 8-1: Lantheus Medical Imaging Product Pipeline

- AREVA Med
- Actinium Pharmaceuticals
- Avid Radiopharmaceuticals
- Bayer HealthCare Pharmaceuticals
- Cardinal Health
- GE Healthcare
- Immunomedics
- Ion Beam Applications
- Lantheus Medical Imaging
- Lantheus Medical Imaging
- Merck & Co
- Navidea
- Nordion
- PETNET Solutions (Siemens Healthcare Global)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos